[Pamela Ely ]

Pamela Ely


Dr. Ely received her BA in Philosophy in 1972 from the University of Rochester, her MA in Philosophy in 1973 from the University of Toronto and her M.D. in 1983 from McGill University. Following a residency in Internal Medicine at the Montreal General Hospital, Dr. Ely completed an Hematology Fellowship in 1989 at the University of Minnesota Hospital. In 1990, Dr. Ely joined the faculty of the Dartmouth Medical School as a hematologist for the Hematology/BMT Program.


Dr. Ely's clinical and research interests are in lymphoma. Her lab is investigating various methods of immunomodulation including utilization of bispecific antibodies and the ex-vivo activation of immune effector cells.


Ericson SG, Coleman KD, Wardwell K, Baker S, Fanger MW, Guyre PM, and Ely P. Monoclonal antibody 197 (anti-FcgRI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down modulation of FcgRI on circulating monocytes. Brit J of Haematology, 92, 1996.

Ely P, Lowrey C, Mills LE, Hermann D, Stearns D, Brighton S, Roach M, Harjes J, Mott L, Lamm G, and Kritz A. High dose chemotherapy with BVAC, autologous bone marrow transplantation and primed peripheral blood stem cells yields durable remissions without excessive toxicity in non-Hodgkin's lymphoma. (Presented as a poster, Keystone Symposia on Molecular & Cellular Biology: Blood Cell and Bone Marrow Transplants, January 1996).

Ely P, Li O, Lowrey C, Kritz A, Hermman D, and Mills L. Presence of HER-2/neu positive cells by RT-PCR in bone marrow harvests of patients undergoing bone marrow transplant for breast cancer does not predict relapse. (Presented as a poster, ASH, Orlando, FL, December 1996).